更新于：2024-11-21

Nemifitide ditriflutate

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

合成多肽

别名

Nemifitide、Nemifitide ditriflutate (USAN)、Netamiftide

+ [2]

靶点

5-HT2A receptor x SERT

作用机制

5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂)

治疗领域

其他疾病

在研适应症-

非在研适应症

重度抑郁症

原研机构

Tetragenex Pharmaceuticals, Inc.

在研机构-

非在研机构

Tetragenex Pharmaceuticals, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C35H44F4N10O8

InChIKeyNIFCNWVWGSEYEP-XYYXENNDSA-N

CAS号204992-09-6

查看全部结构式(2)

序列信息

Sequence Code 14456268

关联

100 项与 Nemifitide ditriflutate 相关的临床结果

登录后查看更多信息

100 项与 Nemifitide ditriflutate 相关的转化医学

登录后查看更多信息

100 项与 Nemifitide ditriflutate 相关的专利（医药）

登录后查看更多信息

项与 Nemifitide ditriflutate 相关的文献（医药）

2009-06-01·Current Opinion in Chemical Biology2区 · 生物学

Emerging targets for antidepressant therapies

2区 · 生物学

Review

作者: Charles B Nemeroff ; Jeffrey J Rakofsky ; Paul E Holtzheimer

Despite adequate antidepressant monotherapy, the majority of depressed patients do not achieve remission. Even optimal and aggressive therapy leads to a substantial number of patients who show minimal and often only transient improvement. In order to address this substantial problem of treatment-resistant depression, a number of novel targets for antidepressant therapy have emerged as a consequence of major advances in the neurobiology of depression. Three major approaches to uncover novel therapeutic interventions are: first, optimizing the modulation of monoaminergic neurotransmission; second, developing medications that act upon neurotransmitter systems other than monoaminergic circuits; and third, using focal brain stimulation to directly modulate neuronal activity. We review the most recent data on novel therapeutic compounds and their antidepressant potential. These include triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, and dopamine receptor agonists. Compounds affecting extra-monoamine neurotransmitter systems include CRF(1) receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Focal brain stimulation therapies include vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS).

2008-12-01·Current Psychiatry Reports2区 · 医学

Novel targets for antidepressant therapies

2区 · 医学

Review

作者: Nemeroff, Charles B ; Holtzheimer, Paul E

Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, N-methyl-D-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.

2008-01-01·International Clinical Psychopharmacology4区 · 医学

Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients

4区 · 医学

Article

作者: Freed, Jeffrey S ; Feighner, John P ; Hlavka, Joseph ; Cartwright, Kenneth ; Sverdlov, Lev ; Nicolau, Gabriela

Clinical data were evaluated from an open-label, single-center, pilot study in patients with chronic refractory depression. The primary efficacy criterion was the change from baseline using the Montgomery-Asberg Depression Rating Scale. The secondary efficacy criteria were the 17-item Hamilton Depression Rating Scale and the Clinical Global Impression-Improvement scale. Response to treatment (40-240 mg once per day by subcutaneous injection for 10-20 doses) was defined as more than 50% improvement in the Montgomery-Asberg Depression Rating Scale from baseline or Clinical Global Impression-Improvement < or =2 and lasting for at least two sequential weeks. Patients with a sustained response at the end point in the acute main treatment phase were enrolled for up to 2 years in a maintenance phase of the study to determine duration of response and to initiate retreatments upon relapse. Of the 25 patients with chronic refractory depression, 11 patients showed a response for Montgomery-Asberg Depression Rating Scale and one responded according to the secondary criterion Hamilton Depression Rating Scale. In seven of the 11 responders to Montgomery-Asberg Depression Rating Scale the effects were sustained for the remainder of the acute phase. Two additional sustained responders identified according to secondary criteria (Hamilton Depression Rating Scale or Clinical Global Impression-Improvement) were also enrolled in the maintenance phase. All nine sustained responders were retreated, as needed, in the maintenance phase of the study, ranging from 71 to 660 days. Mean duration of response following initial treatment and between retreatments was around 2 months. Pharmacokinetic data indicated dose-proportional systemic exposure to the drug.

100 项与 Nemifitide ditriflutate 相关的药物交易

登录后查看更多信息